Neurotech International Ltd
Neurotech International Limited, a clinical-stage biopharmaceutical development company, engages in the research, design, development, and manufacture of medical devices and solutions in Australia. The company focuses on development and commercialization of NTI164 for multiple paediatric neurological disorders; and Mente, a clinically proven home therapy aimed at enhancing engagement and relaxati… Read more
Neurotech International Ltd (NTI) - Net Assets
Latest net assets as of December 2025: AU$5.88 Million AUD
Based on the latest financial reports, Neurotech International Ltd (NTI) has net assets worth AU$5.88 Million AUD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$6.81 Million) and total liabilities (AU$932.85K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | AU$5.88 Million |
| % of Total Assets | 86.3% |
| Annual Growth Rate | 9.08% |
| 5-Year Change | -23.49% |
| 10-Year Change | -79.6% |
| Growth Volatility | 359.91 |
Neurotech International Ltd - Net Assets Trend (2015–2025)
This chart illustrates how Neurotech International Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Neurotech International Ltd (2015–2025)
The table below shows the annual net assets of Neurotech International Ltd from 2015 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | AU$2.95 Million | -75.17% |
| 2024-06-30 | AU$11.90 Million | +200.32% |
| 2023-06-30 | AU$3.96 Million | +177.06% |
| 2022-06-30 | AU$1.43 Million | -62.97% |
| 2021-06-30 | AU$3.86 Million | +697.48% |
| 2020-06-30 | AU$-646.29K | -317.30% |
| 2019-06-30 | AU$297.41K | -92.97% |
| 2018-06-30 | AU$4.23 Million | -1.49% |
| 2017-06-30 | AU$4.30 Million | -70.34% |
| 2016-06-30 | AU$14.48 Million | +1018.47% |
| 2015-12-31 | AU$1.29 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Neurotech International Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5098077200.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | AU$48.91 Million | 1655.56% |
| Other Comprehensive Income | AU$6.20 Million | 209.72% |
| Other Components | AU$1.00 | 0.00% |
| Total Equity | AU$2.95 Million | 100.00% |
Neurotech International Ltd Competitors by Market Cap
The table below lists competitors of Neurotech International Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Genius Metals Inc
PINK:GNSMF
|
$7.34 Million |
|
Axteria Group Bhd
KLSE:7120
|
$7.34 Million |
|
Atlanta Poland SA
WAR:ATP
|
$7.34 Million |
|
Raiden Resources Ltd
AU:RDN
|
$7.34 Million |
|
Saigon Viendong Technology JSC
VN:SVT
|
$7.33 Million |
|
Prakash Steelage Limited
NSE:PRAKASHSTL
|
$7.33 Million |
|
NewHold Investment Corp III Warrants
NASDAQ:NHICW
|
$7.33 Million |
|
SMRT Holdings Bhd
KLSE:0117
|
$7.33 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Neurotech International Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 11,898,687 to 2,954,549, a change of -8,944,138 (-75.2%).
- Net loss of 10,598,859 reduced equity.
- New share issuances of 429,526 increased equity.
- Other comprehensive income decreased equity by 524,806.
- Other factors increased equity by 1,750,001.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | AU$-10.60 Million | -358.73% |
| Share Issuances | AU$429.53K | +14.54% |
| Other Comprehensive Income | AU$-524.81K | -17.76% |
| Other Changes | AU$1.75 Million | +59.23% |
| Total Change | AU$- | -75.17% |
Book Value vs Market Value Analysis
This analysis compares Neurotech International Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 4.21x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.11x to 4.21x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-06-30 | AU$0.11 | AU$0.01 | x |
| 2017-06-30 | AU$0.06 | AU$0.01 | x |
| 2018-06-30 | AU$0.04 | AU$0.01 | x |
| 2019-06-30 | AU$0.00 | AU$0.01 | x |
| 2020-06-30 | AU$0.00 | AU$0.01 | x |
| 2021-06-30 | AU$0.01 | AU$0.01 | x |
| 2022-06-30 | AU$0.00 | AU$0.01 | x |
| 2023-06-30 | AU$0.00 | AU$0.01 | x |
| 2024-06-30 | AU$0.01 | AU$0.01 | x |
| 2025-06-30 | AU$0.00 | AU$0.01 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Neurotech International Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -358.73%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -433.60%
- • Asset Turnover: 0.75x
- • Equity Multiplier: 1.10x
- Recent ROE (-358.73%) is below the historical average (-265.65%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -64.84% | -390.01% | 0.07x | 2.54x | AU$-968.88K |
| 2016 | -28.95% | -1722.11% | 0.01x | 2.04x | AU$-2.93 Million |
| 2017 | -93.87% | -4565.50% | 0.02x | 1.15x | AU$-4.46 Million |
| 2018 | -94.31% | -13280.17% | 0.01x | 1.09x | AU$-4.41 Million |
| 2019 | -1614.66% | -2468.29% | 0.30x | 2.19x | AU$-4.83 Million |
| 2020 | 0.00% | -2214.72% | 0.96x | 0.00x | AU$-1.65 Million |
| 2021 | -192.43% | -3604.58% | 0.04x | 1.30x | AU$-7.82 Million |
| 2022 | -235.12% | -8787.42% | 0.02x | 1.41x | AU$-3.51 Million |
| 2023 | -196.67% | -130759.17% | 0.00x | 1.34x | AU$-8.19 Million |
| 2024 | -42.60% | -258239.99% | 0.00x | 1.03x | AU$-6.26 Million |
| 2025 | -358.73% | -433.60% | 0.75x | 1.10x | AU$-10.89 Million |
Industry Comparison
This section compares Neurotech International Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $31,815,679
- Average return on equity (ROE) among peers: -60.84%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Neurotech International Ltd (NTI) | AU$5.88 Million | -64.84% | 0.16x | $7.34 Million |
| Adalta Ltd (1AD) | $2.03 Million | -265.03% | 1.74x | $171.91K |
| Algorae Pharmaceuticals Ltd (1AI) | $2.88 Million | -33.65% | 0.18x | $9.99 Million |
| ACRUX Ltd (ACR) | $17.49 Million | -17.99% | 0.05x | $2.16 Million |
| Argenica Therapeutics Ltd (AGN) | $13.95 Million | -39.28% | 0.17x | $11.42 Million |
| Arovella Therapeutics Ltd (ALA) | $11.23 Million | -77.89% | 0.18x | $39.76 Million |
| Anatara Lifesciences Ltd (ANR) | $5.92 Million | -48.49% | 0.08x | $718.75K |
| Bio-Gene Technology Ltd (BGT) | $4.25 Million | -56.43% | 0.18x | $2.33 Million |
| BTC Health Ltd (BTC) | $11.34 Million | -4.81% | 0.03x | $364.22 |
| Cambium Bio Ltd (CMB) | $8.27 Million | -79.86% | 0.16x | $8.11 Million |
| Clinuvel Pharmaceuticals Ltd (CUV) | $240.81 Million | 15.02% | 0.13x | $251.65 Million |